Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

Dundee University spin-out wins deal worth more than £40m

It is a major deal for the Dundee company, which develops molecules for oncology and severe inherited diseases.

Dr Andrew Woodland, chief executive of Tay Therapeutics.
Dr Andrew Woodland, chief executive of Tay Therapeutics. Image: Dundee University.

A University of Dundee spin-out has won a licensing deal potentially worth more than £40 million.

Tay Therapeutics has agreed a deal with VYNE Therapeutics Inc, a US-based biotech firm focused on developing therapies for immuno-inflammatory diseases.

The Dundee company, which develops small molecules for oncology and severe inherited diseases, could receive $50m – more than £40m – in upfront and milestone payments.

The company spun out of the University’s School of Life Sciences in 2020. It now employs 10 people at its Dundee base.

Under the deal, the American firm has licensed exclusive rights to develop Tay Therapeutics’ oral BET inhibitor as a potential treatment for immune-inflammatory and fibrotic disorders.

Dundee firm’s ‘discovery and development’

Tay Therapeutics chief executive Dr Andrew Woodland welcomed the deal.

He said: “The second deal with VYNE is the culmination of two years of discovery and development of BET inhibitors with differentiated selectivity and safety profiles.

“I am delighted for the Tay team and consider VYNE ideally placed to continue developing and maximising the value of the BET inhibitor projects.

“This deal further validates Tay’s business model of growing organically using revenues to support development activities with around £6m received in upfront and milestone payments from the VYNE collaboration to date.”

Tay Therapeutics’ scientists work on bromodomain and extra-terminal domain (BET) inhibitors.

Research has determined a key role for BET inhibitors in inflammatory processes. This means they have the potential to treat a range of immune-inflammatory and fibrotic disorders.

University of Dundee's life sciences building.
University of Dundee’s life sciences building.

TAY-B2, the molecule developed by the Dundee University spin-out and now known as VYN202, has demonstrated potent anti-inflammatory and anti-fibrotic effects in multiple  pre-clinical models.

This led VYNE to exercise its option to progress the molecule for treatment of major immuno-inflammatory conditions with high unmet need.

Tay Therapeutics out-licensed its topical pan-BET inhibitor to VYNE for £16m in 2021.

The out-licensing of both projects will bring potential milestone revenues of over $65m. It will also earn the Dundee firm tiered royalty payments of up to 10% of net annual sales.

American firm’s boss ‘thrilled’

David Domzalski, president and chief executive of VYNE, said: “We are thrilled to be licensing the oral BET project from Tay.

“We look forward to developing an oral BET inhibitor molecule in immuno-inflammatory conditions that we believe, based on pre-clinical results, is potentially best-in-class.”

The Dundee University spin-out will now focus on developing a platform to discover and develop a new class of medicine that can cause the body to ignore specific mutations.

By restoring functional proteins, the drugs seek to address the root cause of these diseases.

Tay is supported by its seed investors o2h Ventures, Meltwind, Wren Capital, Scottish Enterprise and the University of Dundee.

Conversation